Featured

Status

All Statuses
  • Active, not recruiting103

Health Topics

Clear Filters

Search Clinical Trials

103 Results

Active, Not Recruiting
A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare (External Link)
Whole genome sequencing (WGS) and whole exome sequencing (WES) services are currently available to and are being utilized by physicians and their patients in both research and clinical settings. The …
Baylor Role: Collaborator
Active, Not Recruiting
Post-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU) (External Link)
An exclusive human milk protein diet in infants less than 1250 grams birth weight has been shown to reduce the rate of necrotizing enterocolitis, a devastating intestinal disease in premature …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Administration of Donor T Cells With the Caspase-9 Suicide Gene (External Link)
If the patient is doing well after the stem cell transplant, and does not have severe GvHD, s/he will be eligible to receive the special "iCasp9" T cells from Day …
Baylor Role: Lead Sponsor
Active, Not Recruiting
CYP19A1 Gene and Pharmacogenetics of Response to Testosterone Therapy (External Link)
Estrogen has been gaining recognition as the primary hormone that regulates the male skeleton. Estrogen in males is mainly derived from the conversion of testosterone to estradiol by the enzyme …
Baylor Role: Collaborator
Active, Not Recruiting
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (External Link)
The EBV CTLs will be made for specific patients. First blood will be collected from the patient and then the the CD30 chimeric-EBV CTLs will be created in the lab. …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (External Link)
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator
Active, Not Recruiting
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (External Link)
WHAT IS THE OVERALL TREATMENT PLAN AND HOW MANY VACCINATIONS WILL THE PATIENT RECEIVE? There will be several injections of the vaccine scheduled. The first injection will be given 3 …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome (External Link)
This study is one of three projects of an NIH Rare Disease Clinical Research Consortium focused on brain blood vessel malformations in three different rare diseases. The focus of this …
Baylor Role: Collaborator
Active, Not Recruiting
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (External Link)
Because the cells have a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects …
Baylor Role: Lead Sponsor
Active, Not Recruiting
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (External Link)
The patient or their donor will give us blood to make CD19-CD28 chimeric receptor T cells and CD19 chimeric-EBV specific T cells in the laboratory. These cells are grown and …
Baylor Role: Lead Sponsor